Non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50
= 8 - 68 mM). Anticonvulsant in vivo
and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na+
= 161 mM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of AstraZeneca UK Ltd.
Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride.
Palmer et al.
Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes.
Santangeli et al.
Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite.
Subramaniam et al.